Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Greenberg, PL; Stone, RM; Al-Kali, A; Barta, SK; Bejar, R; Bennett, JM; Carraway, H; De Castro, CM; Deeg, HJ; DeZern, AE; Fathi, AT; Head, D ...
Published in: J Natl Compr Canc Netw
January 2017
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2017
Volume
15
Issue
1
Start / End Page
60 / 87
Location
United States
Related Subject Headings
- Survival Rate
- Oncology & Carcinogenesis
- Myelodysplastic Syndromes
- Mutation
- Medical Oncology
- Induction Chemotherapy
- Immunologic Factors
- Humans
- Hematopoietic Stem Cell Transplantation
- Hematinics
Citation
APA
Chicago
ICMJE
MLA
NLM
Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., … Smith, C. (2017). Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(1), 60–87. https://doi.org/10.6004/jnccn.2017.0007
Greenberg, Peter L., Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, et al. “Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 1 (January 2017): 60–87. https://doi.org/10.6004/jnccn.2017.0007.
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jan;15(1):60–87.
Greenberg, Peter L., et al. “Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 15, no. 1, Jan. 2017, pp. 60–87. Pubmed, doi:10.6004/jnccn.2017.0007.
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O’Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jan;15(1):60–87.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2017
Volume
15
Issue
1
Start / End Page
60 / 87
Location
United States
Related Subject Headings
- Survival Rate
- Oncology & Carcinogenesis
- Myelodysplastic Syndromes
- Mutation
- Medical Oncology
- Induction Chemotherapy
- Immunologic Factors
- Humans
- Hematopoietic Stem Cell Transplantation
- Hematinics